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ABSTRACT: Perkinsus marinus, a protozoan parasite of the Eastern oyster Crassostrea virginica, has
severely impacted oyster populations from the Mid-Atlantic region to the Gulf of Mexico coast of
North America for more than 30 yr. Although a chemotherapeutic treatment to reduce or eliminate P.
marinus from infected oysters would be useful for research and hatchery operations, an effective and
practical drug treatment does not currently exist. In this study, the antimicrobial drug triclosan
5-chloro-2-(2, 4 dichlorophenoxy) phenol, a specific inhibitor of Fab1 (enoyl-acyl-carrier-protein
reductase), an enzyme in the Type II class of fatty acid synthetases, was tested for its effects on viability, proliferation and fatty acid synthesis of in vitro-cultured P. marinus meronts. Treatment of P.
marinus meront cell cultures with concentrations of ≥2 µM triclosan at 28°C (a temperature favorable
for parasite proliferation) for up to 6 d stopped proliferation of the parasite. Treatment at ≥5 µM at
28°C greatly reduced the viability and fatty acid synthesis of meront cells. Oyster hemocytes treated
with ≥20 µM triclosan exhibited no significant (p < 0.05) reduction in viability relative to controls for
up to 24 h at 13°C. P. marinus meronts exposed to ≥2 µM triclosan for 24 h at 13°C exhibited significantly (p < 0.05) lower viability relative to controls. Exposure of P. marinus meronts to triclosan concentrations of ≥20 µM resulted in > 50% mortality of P. marinus cells after 24 h. These results suggest
that triclosan may be effective in treating P. marinus-infected oysters.
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The protozoan parasite Perkinsus marinus, causative agent of Dermo disease in the Eastern oyster
Crassostrea virginica, has decimated oyster populations along the Atlantic coast of North America and
the Gulf of Mexico for at least 30 yr. One element
critical to both the restoration of wild oyster populations and the development of commercial aquaculture operations is a practical method for reducing or
eliminating P. marinus from infected oysters. Currently, virtually all oysters in the mid-Atlantic region

are infected with P. marinus (Burreson & RagoneCalvo 1996), which has severe ramifications for
restoration efforts, oyster disease research and commercial oyster aquaculture.
Potential benefits from the development of a protocol
to eliminate Perkinsus marinus from infected oysters
include (1) increasing the quantity and quality of
gametes of oysters conditioned for hatchery spawns;
(2) a reduction in the frequency of spawning required
to maintain specific strains of oysters; (3) production of
disease-free spat; (4) production of disease-free oysters
for use in research on host –parasite interactions.
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To be practical for use in controlling Perkinsus marinus infection, a drug therapy needs to have several
important features: (1) high specific action against the
parasite; (2) low toxicity to the host; (3) application
through direct addition to water in holding containers;
(4) low/no toxicity to humans; (5) low cost and ready
availability. Several studies evaluating potential
chemotherapeutic agents for treatment of Dermo disease have been published, but the protocols so far
developed to successfully treat P. marinus infection in
oysters fail to meet several of these criteria (Ray
1966a,b, Calvo & Burreson 1994, Faisal et al. 1999,
Delaney et al. 2003).
Parasitic protozoans must either acquire lipids from
their host or synthesize lipids de novo to produce the
new cell membrane necessary for cell replication.
Inhibiting the ability to synthesize new membrane prevents the parasite from increasing in surface area,
thereby halting cell proliferation and disease progression.
The antimicrobial drug triclosan, 5-chloro-2-(2, 4
dichlorophenoxy) phenol, has been used in a wide
array of consumer products such as soaps, toothpastes and household plastics for the last 30 yr.
Triclosan inhibits fatty acid synthesis and stops the
proliferation of protozoan parasites including species
of the genera Plasmodium, Toxoplasma, and Trypanosoma in vitro and in vivo (Beeson et al. 2001,
McLeod et al. 2001, Surolia & Surolia 2001, Roberts
et al. 2003). The purpose of the present study was to
determine whether triclosan may be a useful
chemotherapeutic agent to treat oysters infected with
Perkinsus marinus. The effectiveness of triclosan
against P. marinus was evaluated by measuring the
effect of the drug on the growth, viability and fatty
acid synthesis of in vitro parasite cultures. To address
concerns about potential toxic effect on host cells,
the effect of triclosan on oyster hemocyte viability
was also assessed.

MATERIALS AND METHODS
Culture conditions. Perkinsus marinus meront cells
were cultivated as previously described (Chu et al.
2002) in medium defined by La Peyre et al. (1993).
Medium was prepared with artificial seawater (ASW)
and adjusted to an osmolarity of 590 (equivalent to a
salinity of 20, Lund et al. 2004). The medium was then
sterilized by 0.2 µm filtration and stored at 4°C until
use. Meronts were inoculated at a concentration of 1 ×
106 ml–1 and cultivated in 10 ml aliquots of medium in
T-10 tissue-culture flasks at 28°C. Meronts in exponential growth phase (7 d old) were harvested and used for
all assays.

Expt 1. Effect of triclosan on growth, viability and
fatty acid synthesis by Perkinsus marinus. The effects
of triclosan on the fatty acid synthesis rates of P. marinus were tested by measuring the incorporation of
exogenous 13C sodium acetate into fatty acids of
P. marinus meront cells. We added 10 ml aliquots of
fresh media containing 6 mM sodium acetate 1, 2 13C2
(Cambridge Isotope Laboratories) to culture flasks and
inoculated those with 2.5 × 107 cells and 0, 2, 5 or
10 µM triclosan using ethanol (5 µl ml–1) as a carrier
(n = 3). After 72 h at 28°C, cultures were harvested and
cell density and percentage of viable cells for each culture flask was determined using a neutral red assay
(Borenfreund & Puerner 1985), and fatty acid synthesis
rates were determined by gas chromatography/mass
spectroscopy (GC/MS) (Chu et al. 2002).
Expt 2. Viability and cell proliferation of Perkinsus
marinus cultures exposed to different levels of triclosan. To test a wide range of triclosan concentrations, 21 T-10 tissue-culture flasks containing 10 ml
aliquots of medium were inoculated with 1 ml (0.25 ×
106 cells) of 4 d old P. marinus culture. Triclosan solutions of 0, 2, 5, 10, 20, 50 and 100 µM were added with
ethanol (5 µl ml–1) to the culture flasks (3 replicates per
treatment). Aliquots of 1.2 ml from each culture flask
were collected after 3 h, 24 h, 3 d and 6 d incubation at
28°C for determination of cell culture density and viability measurements by flow cytometry (FCM). All the
suspensions were filtered through 80 µm mesh into
FCM tubes and maintained on ice until FCM analysis.
Expt 3. Viability of oyster hemocytes exposed to triclosan. Adult oysters, Crassostrea virginica, were supplied by Pemaquid Oyster Company (Waldoboro) and
maintained in a flow-through seawater system at
ambient temperature (13 to 14°C) and salinity (15 to
20). They were processed as follows: hemolymph was
withdrawn from the adductor muscle through a notch
previously (24 h) ground in the oyster shell, using a
1 ml plastic syringe with a 25-gauge needle. Hemolymph from each oyster was transferred into an individual Eppendorf tube held on ice. Only individual
samples confirmed by microscope observation to be
free of contaminating particles were used. Hemolymph
from 30 individuals was pooled to constitute 3 replicates of 9 ml of fresh hemolymph. Pooled hemolymph
samples were filtered through 80 µm mesh prior to use.
We combined 1 ml of hemolymph with 1 ml of antiaggregant hemocyte solution (AAHS, Auffret &
Oubella 1995) in 21 Falcon vials (7 vials per hemolymph pool), and then added 0, 2, 5, 10, 20, 50 and
100 µM of the ethanol (5 µl ml–1) triclosan solutions to
the 2 ml hemolymph + AAHS mix (3 replicates per
ttreatment). The hemolymph was continuously maintained on ice until initiation of incubation. All the
Falcon tubes were thus incubated at 13°C (the temper-
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ature at which, the oyster were maintained prior to
bleeding). After 24 h incubation, 0.6 ml of each cell
suspension was collected and filtered into FCM tubes
for subsequent FCM analysis.
Expt 4. Viability of Perkinsus marinus meronts
exposed to triclosan at temperature similar to that in
oyster hemocyte challenge. To compare triclosan
treatment of Perkinsus marinus meronts with oyster
hemocytes, meronts were cultured at 13°C for 2 wk
prior to triclosan challenge. Cultures were concentrated by centrifugation at 800 × g for 20 min, and then
used to inoculate 5 ml of fresh medium into each flask
to a final concentration of 106 cells ml–1. Cultures were
exposed to 0, 2, 5, 10, 20, 50 and 100 µM triclosan at
13°C using ethanol (5 µl ml–1) as a carrier (n = 3). The
number of viable meronts after 24 h was determined
using a neutral red viability assay (Borenfreund &
Puerner 1985). The percentage of viable cells was
determined by dividing the number of viable cells in a
treatment by the number of viable cells in controls
(0 µM triclosan).
Measurement of Perkinsus marinus fatty acid synthesis rates by GC/MS. Fatty acid synthesis rates as
measured by 13C incorporation into meront fatty acids
were determined as described previously (Chu et al.
2002). Briefly, cell pellets were freeze-dried and lipids
extracted according to the method of Bligh & Dyer
(1959). An aliquot of approximately 500 µg of lipids
from each sample and 20 µg internal standard (23:0)
were transesterified by addition of 1 ml of 10% BF3
(w/w) in methanol followed by heating for 15 min at
95 to 100°C (Metcalfe & Schmitz 1961). After cooling,
the fatty acid methyl esters (FAME) were extracted
with carbon disulfide (Marty et al. 1992). The organic
phase was evaporated, and the samples dissolved in
hexane.
Separation of FAME was carried out on a GC/FID
(gas chromatograph equipped with a flame ionization
detector) (Varian 3300), using a DBWAX capillary column (J & W, 25 m × 0.32 mm; 0.2 µm film thickness).
The column temperature was programed from 60 to
150°C at 30°C min–1 and 150 to 220°C at 2°C min–1,
injector and detector temperatures were 230 and
250°C, respectively, and the flow rates of compressed
air and hydrogen were 300 and 30 ml min–1. Helium
was used as the carrier gas (2 ml min–1). Identification
of FAMEs was based on the comparison of their retention times with those of authentic standards and confirmed by GC/MS. The quantity of each component
was calculated based on the internal standard.
To detect incorporation of 13C acetate, FAMEs were
further analyzed qualitatively and quantitatively by
mass spectroscopy with a Varian 3400 gas chromatograph equipped with a Varian Saturn 4D GC/MS/MS
detector. Methane was used as the reagent gas for
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positive chemical ionization (CI). The same column as
that used for GC/FID analysis of the FAME samples
(J & W DB-WAX, 25 m × 0.32 mm; 0.2 µm film thickness) was used for GC/MS analysis. Carrier gas
(helium) flow rate was 1 ml min–1. The temperature of
the injection port was 230°C and that of the interface
250°C. The column temperature was programed for a
4 min hold at an initial temperature of 60°C, followed
by a 30°C min–1 increase to 150°C and a subsequent
2°C min–1 increase to 220°C. Data were collected and
processed using Varian Saturn GC/MS software
Version 5.2. FAMEs were identified by retention time
relative to known standards, fragmentation pattern
and mass of the molecular ion. FAMEs containing 13C
derived from acetate were quantified using standard
curves constructed for each FAME standard and ratio
with an internal standard (23:0). The molecular ions in
the spectra of each FAME were used to quantify
masses containing exogenous 13C relative to the native
molecule. Samples from cultures containing unlabeled
sodium acetate were also analyzed in an identical
manner, and served as negative controls for 13C incorporation. Data were expressed as micrograms of fatty
acids containing stable isotope g–1 dry cell pellet h–1.
Determination of cell concentration and viability by
flow cytometry. FCM analysis of Perkinsus marinus
meronts and Crassostrea virginica hemocyte viability
were carried out using a Coulter®‚ EPICS®‚ Altra™
flow cytometer. Briefly, cells were stained with 2
nucleic acid fluorescent dyes: the permeant SYBR
Green I (excitation = 497 nm, emission = 520 nm, commercial
stock solution at 10 000×, molecular probes, S-7563)
and the impermeant propidium iodide, PI, (excitation =
535 nm, emission = 617 nm, Sigma, P4170) at the respective final concentrations of 1× of stock solution
(10 000×) and 10 µg ml–1. SYBR Green I stains both live
and dead cells and PI stains only cells that have lost
membrane integrity (dead cells). The principle of this
assay is that SYBR Green I fluorescence (FL1) differentiates live and dead cells from other particles (e.g. cell
debris) present in the medium and from instrument
‘noise’, while PI allows detection of dead cells on the
FL3 detector. Samples were incubated with the dyes
for 15 min at room temperature prior to analysis. A data
acquisition time of 30 s was sufficient to obtain
between 2000 and 10 000 analyzed cells. Data acquisition was in logarithmic mode (4 decades). To calculate
P. marinus meront cell concentration, the flow rate of
the instrument was measured using a known concentration of 10 µm diameter fluorescent microspheres
(Coulter PN6605359).
Treatment of the FCM data was performed with the
software WinMDI Version 2.8 (Joseph Trotter©).
Perkinsus marinus meronts and oyster hemocytes were
first identified and selected according to 3 FCM para-
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Table 1. Perkinsus marinus. Proliferation, viability and fatty acid synthesis of
meters: forward scatter (FSC), side
cultures after 3 d exposure to triclosan. Initial cell concentrations were 2.5 ×
scatter (SSC) and yellow-green fluores106 cells ml–1. Cell viability measured by uptake of neutral red, fatty acid
cence (FL1). FSC corresponds to the
synthesis by incorporation of 13C-labeled sodium acetate (6 mM) from the
diffracted light on the small angle
medium into Perkinsus marinus fatty acids using gas liquid chromatography/
(detected in line with the incident light
mass spectroscopy. Different superscripts indicate treatments that differed
significantly at the p < 0.05 level. All values are mean ± SD (n = 3)
source) and is proportional to size. SSC
corresponds to the diffracted light on
the right angle and is proportional to
Parameter
Control
Triclosan
the cell complexity or granular content.
(2 µm)
(5 µm)
(10 µm)
FL1 allowed visualization of the SYBRCell conc. (106 cells ml–1) 12.7 ± 0.9a 10.2 ± 0.6ab 7.7 ± 1.7b
1.0 ± 0.2c
green fluorescence of live and dead
% viable cells
85.4 ± 1.3a 84.1 ± 0.5a 74.0 ± 2.4b 11.8 ± 1.7c
cells. After selection, red fluorescence
µg 16:0 g dry wt h–1
70.7 ± 6.1a 55.0 ± 2.4b 14.3 ± 1.7c
8.6 ± 2.1c
a
b
c
allowed visualization of the PI fluoresµg 20:4(n-6)
38.8 ± 3.0
19.1 ± 2.2
8.8 ± 0.6
5.7 ± 1.9 c
<µg dry wt h–1
cence of the dead cells and calculation
of the percentage of viable cells in the
sample.
Statistical analysis. Analysis of variance (ANOVA)
ments relative to the controls and 2 µM treatment
was used to compare the differences in proliferation
(Table 1).
and fatty acid synthesis rates for Perkinsus marinus
Incorporation of 13C from acetate into the initial
meronts exposed to different concentrations of triproduct of fatty acid synthesis, palmitic acid (16:0)
closan (Expt 1) and FCM measurements of cell concen(Table 1), was significantly reduced in all triclosan
tration of P. marinus meronts exposed to different contreatments relative to the controls. Controls had a syncentrations of triclosan for 3 h, 24 h, 3 d and 6 d
thesis rate for palmitic acid of 70.7 ± 6.1 µg g–1 dry wt
h–1, which was significantly higher than that of the 2, 5
(Expt 2). When significant (p < 0.05) treatment effects
and 10 mM triclosan treatments (55.0 ± 2.4, 14.3 ± 1.7
were found, individual comparisons were conducted
and 8.6 ± 2.1 µg g–1 dry wt h–1, respectively) (Table 1).
using Tukey’s Honestly Significant Difference (HSD)
Synthesis of 20:4(n-6) (arachidonic acid), an important
test.
prostaglandin precursor, was also significantly inhibDifferences between percentage of viable Crasited in all triclosan treatments relative to the controls
sostrea virginica hemocytes (Expt 3) and Perkinsus
(Table 1).
marinus meronts (Expt 4) exposed to different concentrations of triclosan for 24 h (Expt 3) at 13°C were
determined using ANOVA. When significant (p < 0.05)
Expt 2
treatment effects were found, individual comparisons
were conducted using Tukey’s HSD test. All percentProliferation rates of Perkinsus marinus cultures
age data were arcsine-transformed prior to statistical
were inhibited by increasing dosages of triclosan relaanalysis. Differences were considered significant
tive to the controls (Fig. 1). At 3 h post-inoculation the
when p < 0.05.
control already had the highest cell density (1.48 ± 0.68
× 105 cells ml–1), but was only significantly higher than
the 5 and 10 µM treatments (1.08 ± 0.05 and 1.13 ±
RESULTS
0.11 × 105 cells ml–1, respectively) (Fig. 1A). From 24 h
on through the 6 d experiment, no treatment above
Expt 1
2 µM had a cell density higher than 1.3 × 105 cells ml–1
(Fig. 1B–D). In contrast, the control treatment inPerkinsus marinus cell cultures incubated with 5
creased from the initial inoculation density of 1 ×
and 10 µM triclosan exhibited lower cell densities and
105 cells ml–1 to 2.32 ± 0.22 × 105 cells ml–1 at 24 h,
lower cell viability than controls (Table 1). The 2 µM
19.31 ± 1.09 × 105 cells ml–1 at 3 d, and 37.40 ± 4.60 ×
triclosan treatment produced a similar trend, but cell
105 cells ml–1 at 6 d (Figs. 1B–D). These values were
density and viability were not significantly lower than
significantly higher (p < 0.05) than in any of the triin the controls. After 3 d incubation, the control culclosan treatments. The culture in the 2 µM treatment
tures had increased from an initial concentration of
proliferated slightly during the course of the experi2.5 × 106 cells ml–1 to 12.7 ± 0.9 × 106 cells ml–1 while
the 2, 5 and 10 µM triclosan treatments had cell densiment, increasing to 1.67 ± 0.08, 3.76 ± 0.15 and 3.69 ±
ties of 10.2 ± 0.6, 7.7 ± 1.7 and 1.0 ± 0.2 × 106 cells
0.61 × 105 cells ml–1 at 24 h, 3 d and 6 d, respectively,
–1
ml , respectively (Table 1). Cell viability was also
but growth was significantly attenuated relative to the
controls (Fig. 1B–D).
significantly (p < 0.05) lower in the 5 and 10 µM treat-
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Fig. 1. Perkinsus marinus. Proliferation of in vitro cultures exposed to triclosan for (A) 3 h, (B) 24 h, (C) 3 d, (D) 6 d measured
by flow cytometry using SYBR Green I/propridium iodide labeling (n = 3). Different letters indicate significant differences at
the p < 0.05 level

Expt 3
Oyster hemocytes treated with triclosan exhibited
mortalities of less than 10% at triclosan concentrations
of < 20 µM for up to 24 h (Fig. 2). No significant (p <
0.05) reduction in viability relative to the controls
occurred at triclosan concentrations below 50 µM.

perature that favors parasite proliferation) at concentrations as low as 2 to 5 µM (Table 1, Fig. 1), and to
reduce cell viability at concentrations as low as 5 µM at
both 28 and 13°C (Table 1, Fig. 2). In contrast, oyster
hemocytes exhibited less than 20% mortality after 24 h
exposure to triclosan concentrations below 50 µM at
120

After 24 h triclosan exposure at 13°C, all Perkinsus
marinus treatments exhibited significantly (p < 0.05)
lower viability relative to the controls (Fig. 3). Incubation at triclosan concentrations ≥20 µM resulted in
> 50% mortality of P. marinus cells, and incubations at
concentrations of ≥50 µM in almost 100% mortality
after 24 h.
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The results of the current study are very encouraging, since triclosan has been shown to inhibit proliferation of Perkinsus marinus in vitro at 28°C (a tem-
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Fig. 2. Crassostrea virginica. Viability of in vitro-cultured
oyster hemocytes exposed to triclosan for 24 h at 13°C (n = 3).
Viability of hemocytes was determined using SYBR Green
I/propridium iodide labeling. Different letters indicate significant differences in viability of treatments at the p < 0.05 level
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Fig. 3. Perkinsus marinus. Viability of in vitro-cultured
meronts exposed to triclosan for 24 h at 13°C (n = 3).
Viability of cultures determined using neutral red assay.
Different letters indicate significant differences in viability
of treatments at the p < 0.05 level

13°C (Fig. 2). This suggests that it may be possible to
treat P. marinus-infected oysters with a concentration of
triclosan that will kill the parasite without substantially
harming the host oyster. To the best of our knowledge,
no studies have yet been conducted on the toxicity of
triclosan to any molluscan species. However, the 48 h
EC50 of triclosan for Ceriodaphnia dubia has been determined to be 400 µg l–1, and triclosan can significantly
reduce survival of rainbow trout fry at a concentration
of 71 µg l–1 (Orvos et al. 2002). As both these levels are
below those tested in the current study (1.5 to 75 mg
l–1), long-term treatment may be potentially harmful to
oysters. However, the high survival rate of oyster hemocytes exposed to triclosan for 24 h suggests that this
drug may prove effective in treating this disease.
Although the results of Expts 1 and 2 revealed a
similar pattern of decreasing cell proliferation and
viability with increasing triclosan concentration, the
threshold concentration for effective repression of
Perkinsus marinus proliferation appeared to vary
between the 2 experiments. In Expt 1, after 3 d, cell
concentration and viability in the 2 µM treatment did
not differ significantly from control values, and cell
concentrations in the 5 µM treatment were still above
inoculum level (Table 1). Only at 10 µM was proliferation completely inhibited (Table 1). In contrast, at
Day 3 in Expt 2, all treatments with triclosan concentrations of 5 µM were equally effective in suppressing
cell proliferation (Fig. 1). These apparent discrepancies may be the result of the lack of synchronicity
of the P. marinus cultures used in the experiments
and/or the different techniques used to measure cell
concentrations in Expts 1 and 2. Since the goal of this
study was to generate in vitro information for design of
in vivo experiments using infected oysters, small inter-

experiment variation in the effective minimum concentration does not diminish the significance of the results.
The attenuated activity of triclosan against Perkinsus
marinus at 13°C (Fig. 3) relative to its activity at 28°C
may be a function of either lower metabolic activity, or
lower drug solubility at colder temperatures. While it
may have been preferable, from the perspective of
experimental design, to conduct the hemocyte assays
in Expt 3 at 28°C, practical issues precluded this. The
oysters used for this study had been procured from a
cold-water environment and maintained at ambient
water temperatures during the winter. Also, it is doubtful that the hemocytes could have been maintained in
vitro for 24 h at elevated temperatures. Phagocytic
activity of oyster hemocytes is reduced at temperatures
> 25°C (Chu & LaPeyre 1993). The greater tolerance of
oyster hemocytes at 13°C relative to the level of triclosan tolerance of the parasite (Figs. 2 & 3) is encouraging and will stimulate further investigations at
higher temperatures.
Previously, several studies have tested different
chemotherapeutic agents for treatment of Dermo disease. Ray (1966a) tested 12 fungicides against Perkinsus marinus in infected oyster tissue by measuring
chemotherapeutic inhibition of parasite enlargement
in fluid thioglycolate medium (FTM). The most promising drug, cycloheximide, completely inhibited enlargement of P. marinus in FTM at concentrations
between 0.25 and 1.0 µg ml–1. Subsequent testing of
cycloheximide on P. marinus-infected oysters demonstrated suppression of P. marinus proliferation in oysters at dosages of 1 to 50 µg ml–1 wk–1 and complete
elimination of the parasite from infected oysters at
50 µg ml–1 wk–1 after 164 d (Ray 1966b). Calvo &
Burreson (1994) screened 8 antifungal antibiotics,
including cycloheximide, both in vitro with FTM and
with P. marinus-infected oysters. Among the drugs
tested, only treatment with cycloheximide (10 µg ml–1)
reduced parasite prevalence. Unfortunately, cycloheximide is now classified by the US Environmental
Protection Agency as a suspected mutagen, making
it unsuitable for use in treating P. marinus-infected
oysters.
Faisal et al. (1999) were able to kill Perkinsus marinus in vitro and in vivo using Bacitracin. However,
they encapsulated the Bacitracin in liposomes for drug
delivery to the oysters, and a very high dosage of the
drug (10 mg ml–1) was required to be effective. Since
liposomes are time-consuming to prepare and have a
useful shelf-life of only a few days, this methodology
may not be practical for use in hatchery or aquaculture
operations. Furthermore, the large quantities of Bacitracin that would be required to treat hundreds or
thousands of oysters would make the procedure prohibitively expensive.
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Delaney et al. (2003) tested the effects of 2 N-halamine compounds, 1, 3-dichloro-2, 2, 5, 5-tetramethyl-4imidaolidinone (DC) and 1-chloro-2, 2, 5, 5-tetramethyl-4-imidazolidinone (MC) on the viability of
Perkinsus marinus cells in seawater. These compounds
apparently damage the outer membrane of P. marinus
cells, thereby inhibiting osmoregulation. DC induced
100% mortality of in vitro-cultured P. marinus cells
after exposure to 44.6 mg l–1 for 8 h, while MC induced
98.6% mortality after 8 h exposure.
Most recently, Elandalloussi et al. (2005) tested the
effects of 9 drugs on the viability of Perkinsus olseni, a
parasite of the clam Ruditapes decussatus, in vitro and
in vivo. Of the drugs tested, only deferoxamine (DFO),
an iron chelator, was effective in reducing, but not
eliminating, P. olseni infection levels in clams when
applied at a concentration of 1 mg l–1 or higher. The
effects of DFO on P. marinus and Crassostrea virginica
are not known, although this would appear to be a
promising drug therapy for Dermo disease worthy of
further pursuit.
While the results of these previous studies are
encouraging, the effective dosage levels of drugs in all
these studies, with the exception of Elandalloussi et
al.’s (2005) study, were considerably higher than those
effective for triclosan. For comparison purposes, the 5,
10 and 20 µM triclosan concentrations used in the present study equate to 1.5, 3 and 6 µg ml–1, respectively.
These are >1000-fold lower than the lowest effective
concentration of Bacitracin (10 mg ml–1) reported by
Faisal et al. (1999), and 1 order of magnitude lower
than the effective dosages of the N-halamine compounds tested by Delaney et al. (2003). None of the
drugs tested by Calvo & Burreson (1994) were effective
against Perkinsus marinus at concentrations <10 mg
l–1. Furthermore, none of the previous studies, except
that of Elandalloussi et al. (2005), tested whether the
applied chemicals and dosages have toxic side-effects
on the host cells.
Enzymes involved in the acquisition and synthesis of
lipids in parasitic protozoans are particularly attractive
drug targets. Several of the pathways used for lipid
synthesis and acquisition by protozoan parasites differ
from those utilized by their hosts (Coombs & Mueller
2002). For example, animals and some fungi use Type I
fatty acid synthetase enzymes for fatty acid synthesis,
while bacteria and plants employ Type II fatty acid
synthetase enzymes. The Type I class differs from the
Type II class in that the former comprise a single multienzyme complex, whereas the latter function as separate enzymes. This affords the potential of creating
drugs that specifically target the parasite with minimal
impact on the host.
Triclosan offers a high degree of pathogen-specificity
because animals use the Type I class of fatty acid syn-
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thetase enzymes for fatty acid synthesis. Recent studies
on triclosan have shown that the drug is a specific inhibitor of Fab1 (enoyl-acyl-carrier-protein reductase),
an enzyme in the Type II class of fatty acid synthetases
that are found in bacteria and plants, but not animals
(Heath et al. 1998, Suguna et al. 2001, Perozzo et al.
2002). This property makes triclosan a potentially
attractive chemotherapeutic agent that can kill pathogens that utilize Type II fatty acid synthetase enzymes
without harming the host animal. Perkinsus marinus is
unique among well-studied parasitic protozoans in that
it synthesizes a wide range of polyunsaturated fatty
acids (Chu et al. 2002). Some metabolites of these
de novo-produced fatty acids apparently contribute to
the virulence of this parasite. Its ability for de novo fatty
acid synthesis and its morphological characteristic (the
presence of a non-photosynthetic plastid in the biflagellate zoospore stage) suggest that this parasite uses
Type II class synthetases (Soudant & Chu 2001, Chu et
al. 2002). The finding that triclosan inhibits fatty acid
synthesis by P. marinus at concentrations as low as
5 µM is consistent with the presence of a Type II fatty
acid synthetase system in this parasite. Although the
genus Perkinsus has been assigned to the phylum Apicomplexa (Levine 1988), recent genetic analysis and
reexamination of the ultrastructure of the parasite suggest that its phylogenetic position is closer to the dinoflagellates than to apicomplexans (Fong et al. 1993,
Flores et al. 1996, Reece et al. 1997, Siddall et al. 1997,
Leander & Keeling 2004). Several recent studies have
shown that the Type II fatty acid synthetases are also
found in some protozoan parasites, including the
apicomplexans Plasmodium falciparum, Toxoplasma
gondii and Trypanosoma sp. (Waller et al. 1998, Kapoor
et al. 2001, McLeod et al. 2001, Suguna et al. 2001,
Surolia & Surolia 2001, Roberts et al. 2003). Triclosan
has been demonstrated to inhibit both fatty acid synthesis and the proliferation of these parasites in vitro
and in vivo (Beeson et al. 2001, McLeod et al. 2001,
Surolia & Surolia 2001). Similarly, the present study has
demonstrated that P. marius meront cells fail to proliferate at triclosan concentrations at or above 5 µM.
In summary, triclosan inhibits growth and greatly
reduces cell viability of in vitro-cultured Perkinsus
marinus. These effects are consistent with a mode of
action in which triclosan acts as an inhibitor of Type II
fatty acid synthetase which has been demonstrated in
bacteria and several Apicomplexan protists (Heath et
al. 1998, Kapoor et al. 2001, McLeod et al. 2001, Suguna et al. 2001, Surolia & Surolia 2001, Perozzo et al.
2002). The observation that triclosan kills P. marinus at
low (5 to 20 µM) concentrations that have minimal
effect on oyster hemocyte viability suggests that this
drug may be useful in treating infected oysters. Further toxicology studies with infected and uninfected
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oysters are required to ultimately determine the utility
of using triclosan to treat Dermo infections in hatchery
and research environs.
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